The pleiotropic effects of PCSK9 in cardiovascular diseases beyond cholesterol metabolism

Area of Science:

• Cardiovascular biology
• Molecular medicine
• Lipid metabolism

Background:

• Cardiovascular diseases (CVD) are a leading global cause of death, with high low-density lipoprotein cholesterol (LDL-C) as a key risk factor.
• Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates LDL-C by degrading hepatic LDL receptors (LDLR).
• PCSK9 inhibitors significantly reduce LDL-C and CVD incidence, but their full clinical impact requires further investigation.

Purpose of the Study:

• To review the multifaceted effects of PCSK9 on cardiovascular diseases (CVD).
• To elucidate the mechanisms underlying PCSK9's role in CVD beyond cholesterol metabolism.
• To explore potential LDLR-independent pathways involving PCSK9 in vascular biology.

Main Methods:

• Literature review of recent studies on PCSK9 function in cardiovascular disease.
• Analysis of research investigating PCSK9 interactions with vascular receptors (e.g., CD36, LRP-1, ABCA1).
• Synthesis of evidence regarding PCSK9's non-cholesterol-related signaling pathways.

Main Results:

• PCSK9 plays a role in CVD through mechanisms independent of its canonical LDLR pathway.
• Local PCSK9 in the vasculature interacts with receptors like CD36, LRP-1, and ABCA1.
• These interactions suggest novel contributions of PCSK9 to cardiovascular pathology.

Conclusions:

• PCSK9 inhibition may offer therapeutic benefits beyond LDL-C reduction.
• Understanding PCSK9's diverse roles is crucial for optimizing its long-term clinical application.
• Further research into PCSK9's non-cholesterol-related functions is warranted for developing targeted CVD therapies.